NCT05685719View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

March 15, 2023

Study Completion Date

November 3, 2023

Conditions
COVID-19 Pneumonia
Interventions
DRUG

STI-1558

An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

DRUG

Itraconazole

A strong CYP3A4 inhibitor

DRUG

Rifampin

A strong CYP3A4 inducer

Trial Locations (1)

Unknown

Zhejiang Xiaoshan Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang ACEA Pharmaceutical Co. Ltd.

INDUSTRY